Bio Green Med Solution (BGMS) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-4/A for Q2 FY2026, filed Sep 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BGMS SEC filings page.
Bio Green Med Solution, Inc. (BGMS) reported $747K in revenue for fiscal year 2025, up 1637.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Operations remain externally funded, even though FY2025 brought a smaller loss and a much stronger reported balance-sheet position.
Cash conversion remains weak: FY2025 produced a net loss of$3.0M alongside an operating cash outflow of$4.77M , meaning accounting results understated the cash consumed by operations. Financing cash flow of$5.26M more than offset that outflow, so the business was still not funding itself internally.
The expense structure remains far ahead of the sales base: FY2025 SG&A represented
The balance sheet changed materially between FY2024 and FY2025: liabilities exceeded assets in FY2024, but were only
Financial Health Signals
Bio Green Med Solution, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bio Green Med Solution, Inc. scores -77.52, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $454.4M against total assets of $8.2M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bio Green Med Solution, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
Bio Green Med Solution, Inc. reported a net loss of $3.0M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bio Green Med Solution, Inc. generated $336K in revenue in Q2 2026. Against the prior quarter it is down 54.8%.
Bio Green Med Solution, Inc.'s EBITDA was -$418K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Bio Green Med Solution, Inc. reported a net loss of $405K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Bio Green Med Solution, Inc. earned -$0.08 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Bio Green Med Solution, Inc. recorded an outflow of $352K in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Bio Green Med Solution, Inc. held $3.8M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Bio Green Med Solution, Inc.'s quarterly ROE was -5.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 30.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Bio Green Med Solution, Inc. reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BGMS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4/A | Q1'26S-4/A | Q4'25S-4/A | Q3'2510-Q | Q2'25S-4/A | Q1'25S-4/A | Q4'24S-4/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $336K | $743K | N/A | $81K+710.0% | N/A | N/A | $0 | $10K-37.5% |
| R&D Expenses | N/A | N/A | N/A | $5K-99.5% | $68K-96.6% | $822K-70.7% | $880K | $950K-81.9% |
| SG&A Expenses | $497K-60.2% | $389K-90.8% | N/A | $1.0M-18.8% | $1.2M-23.1% | $4.2M+166.4% | $948K | $1.2M-23.9% |
| Operating Income | -$418Kn/m | -$246Kn/m | N/A | -$992Kn/m | -$1.2Mn/m | -$4.2Mn/m | -$1.8M | -$2.2Mn/m |
| EBITDA | -$418K | -$245K | N/A | -$992Kn/m | N/A | N/A | -$1.8M | -$2.2Mn/m |
| Income Tax | $9K+350.0% | $30K | N/A | N/A | $2Kn/m | N/A | $1.2M | -$210Kn/m |
| Net Income | -$405Kn/m | -$197Kn/m | N/A | -$988Kn/m | -$1.3Mn/m | -$81Kn/m | -$3.1M | -$2.0Mn/m |
| EPS (Basic) | -$0.08 | -$0.04 | N/A | -$1.31 | -$0.98 | $0.00 | -$12.45 | -$43.80 |
| EPS (Diluted) | -$0.08 | -$0.04 | N/A | -$1.31 | -$0.98 | $0.00 | -$12.45 | -$43.80 |
| Diluted Shares (Avg) | 6M | 5M | N/A | 2M | 1M | 365,231 | N/A | 44,681 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
BGMS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4/A | Q1'26S-4/A | Q4'25S-4/A | Q3'2510-Q | Q2'25S-4/A | Q1'25S-4/A | Q4'24S-4/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.9M+78.5% | $7.6M+102.6% | $8.2M+99.9% | $8.2M+51.6% | $4.4M-46.3% | $3.7M-39.4% | $4.1M-53.5% | $5.4M-56.9% |
| Current Assets | $6.0M+36.2% | $5.6M+51.4% | $6.3M+70.3% | $6.4M+31.2% | $4.4M-43.1% | $3.7M-23.2% | $3.7M-50.6% | $4.9M-55.8% |
| Cash & Equivalents | $3.8M-11.3% | $3.3M-3.2% | $3.5M+11.7% | $3.8M+28.7% | $4.3M-28.7% | $3.5M+23.3% | $3.1M-7.1% | $3.0M-49.8% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $972K | $947K | $1.4M | $1.4M | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.1M | $1.2M | $1.3M | $725K | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $1.6M | $1.6M | $1.6M | $1.6M | N/A | N/A | N/A | N/A |
| Total Liabilities | $694K-9.9% | $804K+19.6% | $1.3M-78.6% | $1.1M-83.3% | $770K-89.3% | $672K-92.0% | $6.3M-23.5% | $6.4M-22.5% |
| Current Liabilities | $692K-8.9% | $796K+20.1% | $1.3M-78.7% | $1.0M-84.2% | $760K-89.4% | $663K-92.1% | $6.3M-23.2% | $6.4M-22.1% |
| Non-Current Liabilities | $2K-80.0% | $8K-11.1% | $11Kn/m | $60Kn/m | $10K+100.0% | $9K-57.1% | $0-100.0% | $0-100.0% |
| Total Equity | $7.2M+97.2% | $6.8M+120.8% | $6.8Mn/m | $7.1Mn/m | $3.6M+263.5% | $3.1Mn/m | -$2.2M-458.2% | -$970K-122.6% |
| Retained Earnings | -$455.0Mn/m | -$454.6Mn/m | -$454.4Mn/m | -$444.3Mn/m | -$441.8Mn/m | -$440.5Mn/m | -$439.5Mn/m | -$436.4Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
BGMS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4/A | Q1'26S-4/A | Q4'25S-4/A | Q3'2510-Q | Q2'25S-4/A | Q1'25S-4/A | Q4'24S-4/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$352Kn/m | -$278Kn/m | -$33Kn/m | -$434Kn/m | -$1.1Mn/m | -$3.2Mn/m | -$1.4Mn/m | -$3.1Mn/m |
| Depreciation & Amortization | $0 | $1K | $4K+300.0% | $0-100.0% | N/A | N/A | $1K-87.5% | $1K-85.7% |
| Stock-Based Compensation | $1K-85.7% | $1K-99.9% | N/A | $6K-94.4% | $7K-96.3% | $1.7M+720.7% | N/A | $107K-72.6% |
| Capital Expenditures | $0 | $1K | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Free Cash Flow | -$352K | -$279K | N/A | N/A | N/A | N/A | N/A | -$3.1Mn/m |
| Investing Cash Flow | $0 | -$1K | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Financing Cash Flow | $773K-58.9% | $105K-97.1% | -$259K-116.1% | -$3Kn/m | $1.9M-70.1% | $3.6Mn/m | $1.6M+61.5% | -$1Kn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BGMS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-4/A | Q1'26S-4/A | Q4'25S-4/A | Q3'2510-Q | Q2'25S-4/A | Q1'25S-4/A | Q4'24S-4/A | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -124.4% | -33.1% | N/A | -1224.7% | N/A | N/A | N/A | -21770.0% |
| Net Margin | -120.5% | -26.5% | N/A | -1219.8% | N/A | N/A | N/A | -19570.0% |
| Return on Equity | -5.7%+30.6pp | -2.9%-0.3pp | N/A | -13.9% | -36.3%+289.7pp | -2.6% | N/A | N/A |
| Return on Assets | -5.2%+24.8pp | -2.6%-0.4pp | N/A | -12.1%+24.3pp | -29.9%+9.8pp | -2.2%+45.6pp | -74.6% | -36.4%+11.9pp |
| Current Ratio | 8.63+2.9x | 7.06+1.5x | 4.70+4.1x | 6.43+5.7x | 5.77+4.7x | 5.60+5.0x | 0.59-0.3x | 0.77-0.6x |
| Liabilities-to-Equity | 0.10-0.1x | 0.12-0.1x | 0.20 | 0.15 | 0.21-7.0x | 0.22 | N/A | N/A |
| Asset Turnover | 0.04 | 0.10 | N/A | 0.010.0x | N/A | N/A | 0.00 | 0.000.0x |
| FCF Margin | -104.8% | -37.5% | N/A | N/A | N/A | N/A | N/A | -30670.0% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where Bio Green Med Solution, Inc. Ranks
Frequently Asked Questions
What is Bio Green Med Solution, Inc.'s annual revenue?
Bio Green Med Solution, Inc. (BGMS) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio Green Med Solution, Inc.'s revenue growing?
Bio Green Med Solution, Inc. (BGMS) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.
Is Bio Green Med Solution, Inc. profitable?
No, Bio Green Med Solution, Inc. (BGMS) reported a net loss of $3.0M in fiscal year 2025.
What is Bio Green Med Solution, Inc.'s EBITDA?
Bio Green Med Solution, Inc. (BGMS) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bio Green Med Solution, Inc.'s return on equity (ROE)?
Bio Green Med Solution, Inc. (BGMS) has a return on equity of -43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bio Green Med Solution, Inc.'s operating cash flow?
Bio Green Med Solution, Inc. (BGMS) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bio Green Med Solution, Inc.'s total assets?
Bio Green Med Solution, Inc. (BGMS) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Bio Green Med Solution, Inc. spend on research and development?
Bio Green Med Solution, Inc. (BGMS) invested $848K in research and development during fiscal year 2025.
What is Bio Green Med Solution, Inc.'s current ratio?
Bio Green Med Solution, Inc. (BGMS) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.
What is Bio Green Med Solution, Inc.'s liabilities-to-equity ratio?
Bio Green Med Solution, Inc. (BGMS) had a liabilities-to-equity ratio of 0.20 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Bio Green Med Solution, Inc.'s return on assets (ROA)?
Bio Green Med Solution, Inc. (BGMS) had a return on assets of -36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bio Green Med Solution, Inc.'s P/E ratio?
Bio Green Med Solution, Inc. (BGMS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $6.2M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bio Green Med Solution, Inc.'s price-to-sales ratio?
Bio Green Med Solution, Inc. (BGMS) trades at 8.4x sales, its market capitalization divided by $747K revenue, FY2025. The market capitalization is $6.2M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Bio Green Med Solution, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Bio Green Med Solution, Inc. (BGMS) held $3.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Bio Green Med Solution, Inc.'s Altman Z-Score?
Bio Green Med Solution, Inc. (BGMS) has an Altman Z-Score of -77.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bio Green Med Solution, Inc.'s Piotroski F-Score?
Bio Green Med Solution, Inc. (BGMS) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio Green Med Solution, Inc.'s earnings high quality?
Bio Green Med Solution, Inc. (BGMS) reported a net loss of $3.0M while operations used $4.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.